I think Vertex dropped yesterday due to continued less impressive scripts data from IMS. Hopefully, this decrease has been mostly related to the holidays but I think there is more to it than that. Perhaps there was a large backlog of "warehoused" patients that were treated during the first several months after Incivek's approval. In any case, it is still possible Vertex can meet revenue and earnings estimates if royalties from European Incivek sales and the milestone payment from Japan make up for weaker US Incivek sales. It will take some significant news to move this stock back into the 40's and we may get that news soon with results from the Incivek/VX-222/ribavirin study. If that news is not positive, there is the Kalydeco/VX-809 study which could yield positive results with blockbuster potential in the first half of 2012.